<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1828">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04373200</url>
  </required_header>
  <id_info>
    <org_study_id>35RC20_9795_HARMONICOV</org_study_id>
    <secondary_id>2020-A01100-39</secondary_id>
    <nct_id>NCT04373200</nct_id>
  </id_info>
  <brief_title>Human Ab Response &amp; immunoMONItoring of COVID-19 Patients</brief_title>
  <acronym>HARMONICOV</acronym>
  <official_title>Human Ab Response &amp; immunoMONItoring of COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, mono centric study on COVID-19 patients with or without acute respiratory
      distress syndrome (ARDS) to analyse the dynamics of the immune response and to search for
      biomarkers of evolution
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessed by World Health Organisation as a pandemic on March 11, COVID-19 is caused by the
      SARS-CoV-2 coronavirus. The spectrum of its clinical manifestations is strikingly broad and
      extends from mild disease (resembling an ordinary bout of flu or even asymptomatic) to
      pneumonia. The latter cases convey a high risk of evolution towards acute respiratory
      distress syndrome (ARDS), eventually fatal when worsening with cytokine storm and multiple
      organ failure or with superinfection and sepsis. In the absence of overt variations of the
      virus itself, its interactions with the host immune system are likely crucial. Clinical
      features of patients with severe forms of COVID-19 were reported, but immunological
      description of biomarkers for exacerbation and mortality vs recovery remains superficial.
      Globally decreased white blood cells, notably T-cells, suggest that CoV-2 might trigger or
      exploit an immune defect. This could correspond to gaps in immune cell subpopulations,
      kinetics of activation or repertoires. Immune failure would then be responsible for
      exacerbations and a poor outcome in intensive care unit (ICU) patients. The objective of the
      study is to characterize the kinetics of the immune response and of immune dysregulation in
      ARDS patients. In addition to studying severe ARDS patients, an inverse image of immune
      repertoires should appear in healed up patients, after they have reached an undetectable
      viral load and acquired protective antibodies (Abs). Humoral immunity mediated by specific
      anti-viral Abs was a key factor for recovery from SARS-CoV-1 infection, and this is also
      expected for CoV-2, making the Ig repertoire also of special interest for its inclusion of
      anti-viral neutralizing Abs (nAbs).

      Altogether, there is thus an urgent need for high-resolution characterization of the
      anti-CoV-2 immune response, correlating the dynamics of immune activation, cytokine
      production and immune repertoires with clinical evolution. In addition to providing
      biomarkers for prognosis evaluation and for monitoring innovative treatments this will also
      participate to the urgent quest of as many possible monoclonal antibodies (mAb) candidates
      for immunotherapy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2020</start_date>
  <completion_date type="Anticipated">November 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Comparative study with 3 cohorts of 25 adult patients:
Cohort A: 25 COVID-19 associated ARDS
Cohort B: 25 COVID-19 without ARDS
Cohort C: 25 ARDS from other causes</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of increased immune population</measure>
    <time_frame>Month 4</time_frame>
    <description>Blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of decreased immune population</measure>
    <time_frame>Month 4</time_frame>
    <description>Blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of statically different phenotypes compared to control patients</measure>
    <time_frame>Month 4</time_frame>
    <description>Blood sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gain or loss of functional phenotypic markers between D1 and D14</measure>
    <time_frame>Day 14</time_frame>
    <description>Qualitative identification of immune subpopulations showing a significant variation compared to controls and quantification of this variation (at D1 and/or D14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gain or loss of functional phenotypic markers between between acute and mild infections</measure>
    <time_frame>Day 14</time_frame>
    <description>Qualitative identification of immune subpopulations showing a significant variation between acute and mild COVID-19 and quantification of this variation (at D1 and/or D14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gain or loss of functional phenotypic markers between D1 and month 4</measure>
    <time_frame>Month 4</time_frame>
    <description>Qualitative identification of immune subpopulations showing a significant variation between acute stage and recovery (at 4 months) and quantification of this variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of V, D, J gene usage alterations in the immunoglobulin and T cell receptor (TCR) repertoires during ARDS linked to COVID-19</measure>
    <time_frame>Day 14</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of the Ig classes and of V, D, J sequences of anti-CoV-2 antibodies</measure>
    <time_frame>Month 4</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of a new set of human antibodies from patients who have recovered of COVID-19</measure>
    <time_frame>Month 4</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>SARS-CoV-2 Coronavirus</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>COVID-19 patients with associated ARDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 patients without associated ARDS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with ARDS from other causes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples collection</intervention_name>
    <description>Blood sample collection at Day 1, day 7, day 14 for all patients. At month 4 for 25 survivors COVID-19 patients</description>
    <arm_group_label>COVID-19 patients with associated ARDS</arm_group_label>
    <arm_group_label>COVID-19 patients without associated ARDS</arm_group_label>
    <arm_group_label>Patients with ARDS from other causes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saliva collection</intervention_name>
    <description>Saliva collection at Month 4 for 25 survivors COVID-19 patients</description>
    <arm_group_label>COVID-19 patients with associated ARDS</arm_group_label>
    <arm_group_label>COVID-19 patients without associated ARDS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient older than 18 years old

          -  Patients COVID-19 :

               -  hospitalized for less than 48 hours in intensive care unit (ICU) with ARDS
                  (PaO2/Fi02 &lt; 200) or

               -  hospitalized with respiratory syndrome without need of invasive mechanical
                  ventilation

          -  Patients hospitalized for less than 48 hours in intensive care unit (ICU) with ARDS
             (PaO2/Fi02 &lt; 200) from other causes

          -  Patients who have given their consent or included in an emergency situation

          -  Patients affiliated to medical care insurance

        Exclusion Criteria:

          -  Pregnant women

          -  Preexisting immune disorders (HIV-infection, malignancy, graft, treatment with
             immunosuppressive agents)

          -  Patients legally protected (under judicial protection, guardianship), persons deprived
             of liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florian REIZINE, MD</last_name>
    <phone>02 99 28 42 48</phone>
    <email>florian.reizine@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian REIZINE, MD</last_name>
      <email>florian.reizine@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc TADIE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu LESOUHAITIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karin TARTE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel COGNE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MikaÃ«l ROUSSEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle GOUIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre MANSOUR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2 coronavirus</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

